INSERM U1218, Institut Bergonié, F-33000, Bordeaux, France.
University of Bordeaux, F-33000, Bordeaux, France.
Sci Rep. 2017 Jul 14;7(1):5480. doi: 10.1038/s41598-017-05726-x.
We previously reported the CINSARC signature as a prognostic marker for metastatic events in soft tissue sarcomas, breast carcinomas and lymphomas through genomic instability, acting as a major factor for tumor aggressiveness. In this study, we used a published resource to investigate CINSARC enrichment in poor outcome-associated genes at pan-cancer level and in 39 cancer types. CINSARC outperformed more than 15,000 defined signatures (including cancer-related), being enriched in top-ranked poor outcome-associated genes of 21 cancer types, widest coverage reached among all tested signatures. Independently, this signature demonstrated significant survival differences between risk-groups in 33 published studies, representing 17 tumor types. As a consequence, we propose the CINSARC prognostication as a general marker for tumor aggressiveness to optimize the clinical managements of patients.
我们之前通过基因组不稳定性报告了 CINSARC 特征作为软组织肉瘤、乳腺癌和淋巴瘤中转移事件的预后标志物，它是肿瘤侵袭性的主要因素。在这项研究中，我们使用已发表的资源在泛癌水平和 39 种癌症类型中调查了 CINSARC 在不良预后相关基因中的富集情况。CINSARC 的表现优于 15000 多个定义明确的特征（包括与癌症相关的特征），在 21 种癌症类型中排名靠前的不良预后相关基因中富集，在所有测试的特征中达到最广泛的覆盖范围。独立地，该特征在 33 项发表的研究中代表 17 种肿瘤类型的风险组之间显示出显著的生存差异。因此，我们提出 CINSARC 预后作为肿瘤侵袭性的一般标志物，以优化患者的临床管理。
